title: [Perioperative management of the patient with atypical Parkinson disease].
abstract: Recent neuropathological findings define that 10-20% of the Parkinson patients belong to the atypical Parkinson's syndrome due to multi-system disease marked by typical Parkinsonian symptoms such as rigor, tremor and akinesia and early onset of severe autonomic, cerebellar or pyramidal disorders. Symptoms like postural hypotension, dysphagia, hypersalivation, urinary bladder dysfunction, thermodysregulation, abnormalities in eye movement, early falls or dementia etc. are frequently seen in these patients. In these patients dopamin depletion in the nigrostriatal pathway is combined with degeneration of other cerebral structures like olivopontocerebellar and intermediolateral columns. Patients need high dosages of L-dopa and other antiparkinsonian drugs with poor prognosis in general. First, we report on an atypical Parkinson patient who developed acute dyspnoea and muscle rigidity after general anaesthesia; second, on another patient who took a long time to recover from general anaesthesia. Both responded to antiparkinsonian drugs, the first to orally applied L-dopa, the second to intravenous amantadine. Most probably the interruption of the treatment with high dosages of L-dopa (in these patients given in 2-4 hours intervals) had caused these complications. The special nature of the anaesthesiological management of atypical Parkinson patients is reviewed.
authors.affiliation: Abteilung für Anästhesiologie, Universitäts-Krankenhaus Eppendorf, Hamburg.
authors.forename: I
authors.initials: I
authors.lastname: Rundshagen
mesh_terms: D000547:Amantadine / Q000008:administration & dosage; D000768:Anesthesia, General; D000978:Antiparkinson Agents / Q000008:administration & dosage; D003342:Corpus Striatum / Q000187:drug effects / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology; D006801:Humans; D007431:Intraoperative Complications / Q000503:physiopathology / Q000517:prevention & control; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009434:Neural Pathways / Q000187:drug effects / Q000503:physiopathology; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000150:complications / Q000503:physiopathology*; D011183:Postoperative Complications / Q000503:physiopathology / Q000517:prevention & control; D011292:Premedication; D011300:Preoperative Care / Q000379:methods*; D013378:Substantia Nigra / Q000187:drug effects / Q000503:physiopathology
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D000547:Amantadine; D004298:Dopamine